Androgen receptor Expression, impact on survival and its Correlation to Clinico-pathological Factors in Breast Cancer
Association of Breast Surgery ePoster Library. Jalini L. 05/15/17; 166317; P043
Ms. L Jalini
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Introduction
Androgen receptor(AR) is the most common steroid receptor present in normal breast tissue, and is expressed in 70-90% breast tumors. The expression of AR, oestrogen (ER) and progesterone (PR) receptors as detected by Immunohistochemistry (IHC)and its correlation with clinicopathological factors and survival was studied.
Method
148 cases with 9.5 years follow-up were selected. Case notes were reviewed to determine clinicopathological factors The Quick and Allred scores were used to assess receptor status. The correlation between the AR and clinicopathological factors were examined using the χ2 test with P value <0.05 as significant. Disease-free survival (DFS) and overall survival (OS) curves were generated using the Kaplan–Meier method
Results
69 (46.6%) of samples were positive for AR expression. Within this group, 29 (42%) 18 (26.1%) and 22 (31.9%) were weakly(AR+), moderately(AR2+) and strongly positive(AR3+). ER expression was detected in 100 of sample (67.6%)(ER+); PR expression was seen in 96 of samples (64.9%).
There was a significant correlation between AR expression and tumour size (χ²=11.34, p=0.0268), AR and ER (χ²=15.17, P<0.0001) and AR and PR expression (χ²=8.095, p<0.0044).
The AR3+ showed better OS than those with weakly positive or negative tumours (p=0.034, p=0.04). There was a significant difference in OS and DFS between luminal (ER+AR+), Basal(ER-AR-) and molecular apocrine (ER-AR+) Tumours.
Furthermore, these results were sustained in ER+AR3+ group but not in ER+AR2+ or AR1+ subgroups.
Conclusion
AR activity may play different roles in different subtypes of breast cancer, necessitating diverse AR targeting strategies that can suppress or activate AR signaling.
Androgen receptor(AR) is the most common steroid receptor present in normal breast tissue, and is expressed in 70-90% breast tumors. The expression of AR, oestrogen (ER) and progesterone (PR) receptors as detected by Immunohistochemistry (IHC)and its correlation with clinicopathological factors and survival was studied.
Method
148 cases with 9.5 years follow-up were selected. Case notes were reviewed to determine clinicopathological factors The Quick and Allred scores were used to assess receptor status. The correlation between the AR and clinicopathological factors were examined using the χ2 test with P value <0.05 as significant. Disease-free survival (DFS) and overall survival (OS) curves were generated using the Kaplan–Meier method
Results
69 (46.6%) of samples were positive for AR expression. Within this group, 29 (42%) 18 (26.1%) and 22 (31.9%) were weakly(AR+), moderately(AR2+) and strongly positive(AR3+). ER expression was detected in 100 of sample (67.6%)(ER+); PR expression was seen in 96 of samples (64.9%).
There was a significant correlation between AR expression and tumour size (χ²=11.34, p=0.0268), AR and ER (χ²=15.17, P<0.0001) and AR and PR expression (χ²=8.095, p<0.0044).
The AR3+ showed better OS than those with weakly positive or negative tumours (p=0.034, p=0.04). There was a significant difference in OS and DFS between luminal (ER+AR+), Basal(ER-AR-) and molecular apocrine (ER-AR+) Tumours.
Furthermore, these results were sustained in ER+AR3+ group but not in ER+AR2+ or AR1+ subgroups.
Conclusion
AR activity may play different roles in different subtypes of breast cancer, necessitating diverse AR targeting strategies that can suppress or activate AR signaling.
Introduction
Androgen receptor(AR) is the most common steroid receptor present in normal breast tissue, and is expressed in 70-90% breast tumors. The expression of AR, oestrogen (ER) and progesterone (PR) receptors as detected by Immunohistochemistry (IHC)and its correlation with clinicopathological factors and survival was studied.
Method
148 cases with 9.5 years follow-up were selected. Case notes were reviewed to determine clinicopathological factors The Quick and Allred scores were used to assess receptor status. The correlation between the AR and clinicopathological factors were examined using the χ2 test with P value <0.05 as significant. Disease-free survival (DFS) and overall survival (OS) curves were generated using the Kaplan–Meier method
Results
69 (46.6%) of samples were positive for AR expression. Within this group, 29 (42%) 18 (26.1%) and 22 (31.9%) were weakly(AR+), moderately(AR2+) and strongly positive(AR3+). ER expression was detected in 100 of sample (67.6%)(ER+); PR expression was seen in 96 of samples (64.9%).
There was a significant correlation between AR expression and tumour size (χ²=11.34, p=0.0268), AR and ER (χ²=15.17, P<0.0001) and AR and PR expression (χ²=8.095, p<0.0044).
The AR3+ showed better OS than those with weakly positive or negative tumours (p=0.034, p=0.04). There was a significant difference in OS and DFS between luminal (ER+AR+), Basal(ER-AR-) and molecular apocrine (ER-AR+) Tumours.
Furthermore, these results were sustained in ER+AR3+ group but not in ER+AR2+ or AR1+ subgroups.
Conclusion
AR activity may play different roles in different subtypes of breast cancer, necessitating diverse AR targeting strategies that can suppress or activate AR signaling.
Androgen receptor(AR) is the most common steroid receptor present in normal breast tissue, and is expressed in 70-90% breast tumors. The expression of AR, oestrogen (ER) and progesterone (PR) receptors as detected by Immunohistochemistry (IHC)and its correlation with clinicopathological factors and survival was studied.
Method
148 cases with 9.5 years follow-up were selected. Case notes were reviewed to determine clinicopathological factors The Quick and Allred scores were used to assess receptor status. The correlation between the AR and clinicopathological factors were examined using the χ2 test with P value <0.05 as significant. Disease-free survival (DFS) and overall survival (OS) curves were generated using the Kaplan–Meier method
Results
69 (46.6%) of samples were positive for AR expression. Within this group, 29 (42%) 18 (26.1%) and 22 (31.9%) were weakly(AR+), moderately(AR2+) and strongly positive(AR3+). ER expression was detected in 100 of sample (67.6%)(ER+); PR expression was seen in 96 of samples (64.9%).
There was a significant correlation between AR expression and tumour size (χ²=11.34, p=0.0268), AR and ER (χ²=15.17, P<0.0001) and AR and PR expression (χ²=8.095, p<0.0044).
The AR3+ showed better OS than those with weakly positive or negative tumours (p=0.034, p=0.04). There was a significant difference in OS and DFS between luminal (ER+AR+), Basal(ER-AR-) and molecular apocrine (ER-AR+) Tumours.
Furthermore, these results were sustained in ER+AR3+ group but not in ER+AR2+ or AR1+ subgroups.
Conclusion
AR activity may play different roles in different subtypes of breast cancer, necessitating diverse AR targeting strategies that can suppress or activate AR signaling.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}